

The Board (“Board”) of Directors (“Directors”) of Wanji Pharmaceutical Holdings Limited (the “Company”) is pleased to announce the unaudited condensed consolidated interim accounts of the Company and its subsidiaries (collectively the “Group”) for the six months ended 30 September 2004 (the “interim accounts”) together with the comparative figures for the corresponding period in 2003. The interim accounts have been reviewed by the Company’s audit committee.

**CONDENSED CONSOLIDATED PROFIT AND LOSS ACCOUNT
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2004**

	<i>Note</i>	Unaudited	
		Six months ended	
		30 September	
		2004	2003
		<i>HK\$'000</i>	<i>HK\$'000</i>
Turnover	2	7,402	8,934
Cost of sales		(4,405)	(5,452)
Gross profit		2,997	3,482
Other revenues	2	1,359	1,281
General and administrative expenses		(6,243)	(6,570)
Operating loss	3	(1,887)	(1,807)
Financial costs	4	(342)	(355)
Loss before taxation		(2,229)	(2,162)
Taxation	5	–	–
Loss attributable to shareholders		(2,229)	(2,162)
Basic loss per share	7	(0.04 cents)	(0.04 cents)
Diluted loss per share	7	N/A	N/A